Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01542736 · ClinicalTrials.gov registry record · Phase 2
Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01542736 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 8 participants.
The verdict
NCT01542736, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.
Interventions
- DRUG Carboplatin
- DRUG Vincristine
- RADIATION 24 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-05 |
| Est. Completion | 2020-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01542736
The ClinicalTrials.gov registry entry for NCT01542736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01542736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01542736 about?
NCT01542736 is a clinical study titled "Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)". The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratent...
What is the current status of trial NCT01542736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2020-09.
What interventions are being tested in trial NCT01542736?
The interventions under investigation include: Carboplatin (DRUG), Vincristine (DRUG), 24 Gy (RADIATION).
Who is sponsoring clinical trial NCT01542736?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.